Dr. Maliik is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
731 E. Yosemite Ave
Ste B, PMB 325
Merced, CA 95348Phone+1 909-223-2075
Education & Training
- King Edward Medical UniversityClass of 1977
Awards, Honors, & Recognition
- Shams-uz-Zaman medal Pakistan Society of Clinical Oncology, 2002
- Distinguished Service Award Pakistan Society of Clinical Oncology, 2000
- Award, Distinguished Investigator from a developing country Australian Cancer Society, 1992
- Join now to see all
Publications & Presentations
Journal Articles
- Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: A randomized phase II studyInfante JR, Reid TR, Cohn AL, Edenfield WJ, Cescon TP, Hamm JT, Malik IA, et al, Cancer, 1/1/2013
- A phase I study of capecitabine, irinotecan, celecoxib & radiation as neoadjuvant therapy of patients with locally advanced rectal cancerMalik I, Hussein F, Bush D, et al, Am J Clin Oncol, 1/1/2010
- Reduction of neutropenia and febrile neutropenia in colorectal cancer patients receiving pegfilgrastim with every-2-week chemotherapyHecht JR, Pillai M, Gollard R, Heim W, Swan F, Patel R, Dreiling L, Mo M, Malik I, Clin Colorectal Cancer, 1/1/2010
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Pegfilgrastim in colorectal cancer (CRC) patients (pts) receiving every-two-week (Q2W) chemotherapy (CT): Long-term results from a phase 2, randomized, controlled study.Hecht JR, Pillai M, Gollard R, Dreiling L, Mo M, Malik I, Proc Am Soc Clin Oncol, 1/1/2009
- Pegfilgrastim reduces the incidence of neutropenia in patients with locally advanced or metastatic colon cancer receiving chemotherapy administered every 2 weeks as fi...Malik I, Gollard R, Patel R, Tomita D, Dreiling L, Hecht, J, Support Care Cancer, 1/1/2007
- Panitumumab activity in metastatic colorectal cancer (mCRC) patients (pts) with low or negative tumor epidermal growth factor receptor (EGFr) levels: an updated analysis.Mitchell E, Hecht JR, Baranda J, Malik I, et al, Proc Am Soc Clin Oncol, 1/1/2007
- Join now to see all
Lectures
- Pegfilgrastim in colorectal cancer (CRC) patients (pts) receiving every-two-week (Q2W) chemotherapy (CT): Long-term results from a phase 2, randomized, controlled study.Orlando, FL - 1/29/2009
- Effectiveness of darbepoetin alpha administered every 3 weeks on clinical outcomes in patients with gastrointestinal cancer and chemotherapy induced anemia.San Francisco, CA - 1/18/2006
- Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer.Orlando, FL - 1/13/2005
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: